Biohaven (BHVN) SVP Kimberly Gentile Receives Stock Award

What Happened

• Kimberly Gentile, SVP, Clinical Operations at Biohaven Ltd. (BHVN), was listed on a Form 4 for a grant of 1,000 shares (derivative/stock option) on September 15, 2026. The reported acquisition price is $0.00, and the instrument is a stock option (derivative), not an open-market purchase or sale.
• The filing notes the option was granted in connection with the commencement of employment by the Reporting Person's son; Gentile disclaims beneficial ownership of the securities held by her son.

Key Details

• Transaction date: 2026-09-15; Form filed: 2026-09-17 (appears timely — filed within two business days).
• Transaction type/code: A (Award/Grant); amount: 1,000 shares; price: $0.00.
• Shares owned after transaction: Not specified in the summarized filing for the Reporting Person.
• Footnotes: (F1) underlying option vests in four equal installments on 9/15/2026, 2027, 2028 and 2029, subject to the Reporting Person's son's continuous service; (F2) grant was to her son and Gentile disclaims beneficial ownership.

Context

• This is a derivative award (stock option) granted to the reporting person's son—no exercise or sale occurred. Grants to family members are disclosed under Section 16 reporting rules but do not necessarily reflect the reporting person's personal trading intent.
• The $0 reported reflects the grant/award terms; vesting and the son's continued employment determine when (and if) the options become exercisable.